A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
Trial ID or NCT#
Status
Purpose
The objectives of this study are to evaluate the safety and efficacy of Zimura (avacincaptad pegol) intravitreal administration in patients with geographic atrophy secondary to age-related macular degeneration (AMD)
Official Title
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Eligibility Criteria
- * Subjects of either gender aged ≥ 50 years* Diagnosis of Non-foveal GA secondary to dry AMD
- * Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals* Any intraocular surgery or thermal laser within 3 months of trial entry.* Any prior thermal laser in the macular region, regardless of indication* Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks.* Previous therapeutic radiation in the region of the study eye* Any sign of diabetic retinopathy in either eye
Investigator(s)
View on ClinicalTrials.gov